Group 1: 华盛锂电 - Company plans to invest in a project to produce 60,000 tons of vinyl carbonate annually, with the first phase targeting 30,000 tons [1] - Total investment for the project is approximately 950 million yuan, funded by the company's own or raised funds [1][2] Group 2: 万里扬 - Shareholder plans to reduce holdings by up to 1.5% of the company's total shares, equating to a maximum of 19.69 million shares [3] - The reduction is due to the shareholder's own funding needs [3][4] Group 3: 云南旅游 - Company intends to raise no more than 191 million yuan through a private placement of up to 304 million shares [5] - Funds will be used for the construction of a cultural tourism equipment industrial park and to repay debts [5][6] Group 4: 冠农股份 - Company reported a 71.58% decline in net profit for 2024, amounting to 205 million yuan [9] - Revenue decreased by 11.15% to 3.863 billion yuan, with a proposed cash dividend of 0.8 yuan per 10 shares [9][10] Group 5: 华光新材 - Company achieved a 93.78% increase in net profit for 2024, totaling 80.6174 million yuan [11] - Revenue grew by 35.52% to 1.918 billion yuan, with a proposed cash dividend of 2.77 yuan per 10 shares [11][12] Group 6: 南大光电 - Company reported a 28.15% increase in net profit for 2024, reaching 271 million yuan [13] - Revenue increased by 38.08% to 2.352 billion yuan, with a proposed cash dividend of 1 yuan per 10 shares and a stock bonus of 2 shares for every 10 shares held [13][14] Group 7: 博瑞医药 - Company experienced a 6.57% decrease in net profit for 2024, amounting to 189 million yuan [15] - Revenue increased by 8.74% to 1.283 billion yuan, with a proposed cash dividend of 0.96 yuan per 10 shares [15][16] Group 8: 贵州茅台 - Company reported a 15.38% increase in net profit for 2024, totaling 862 million yuan [17] - Revenue grew by 15.71% to 170.9 billion yuan, with a proposed cash dividend of 276.24 yuan per 10 shares [17][18] Group 9: 西部建设 - Company reported a net loss of 263 million yuan for 2024, compared to a profit of 645 million yuan in 2023 [19] - Revenue decreased by 11.01% to 20.347 billion yuan, with a proposed cash dividend of 1.25 yuan per 10 shares [19][20] Group 10: 锡业股份 - Company achieved a 2.55% increase in net profit for 2024, totaling 1.444 billion yuan [21] - Revenue slightly decreased by 0.91% to 41.973 billion yuan, with a proposed cash dividend of 1.9 yuan per 10 shares [21][22] Group 11: 海天味业 - Company reported a 12.75% increase in net profit for 2024, amounting to 6.344 billion yuan [23] - Revenue increased by 9.53% to 26.901 billion yuan, with a proposed cash dividend of 8.6 yuan per 10 shares [23][24] Group 12: 台基股份 - Company experienced an 18.77% decrease in net profit for 2024, totaling 25.2935 million yuan [25] - Revenue increased by 10.76% to 354 million yuan, with a proposed cash dividend of 0.8 yuan per 10 shares [25][26] Group 13: 金盘科技 - Company reported a 13.82% increase in net profit for 2024, amounting to 574 million yuan [27] - Revenue grew by 3.5% to 6.901 billion yuan, with a proposed cash dividend of 5.06 yuan per 10 shares [27][28] Group 14: 中油资本 - Company reported an 8.14% decrease in net profit for 2024, totaling 4.652 billion yuan [29] - Revenue slightly increased by 0.08% to 39.024 billion yuan, with a proposed cash dividend of 0.57 yuan per 10 shares [29][30] Group 15: 锐捷网络 - Company achieved a 43.09% increase in net profit for 2024, amounting to 574 million yuan [31] - Revenue increased by 1.36% to 11.699 billion yuan, with a proposed cash dividend of 6.06 yuan per 10 shares and a stock bonus of 4 shares for every 10 shares held [31][32] Group 16: 华瓷股份 - Company reported a 14.21% increase in net profit for 2024, totaling 205 million yuan [33] - Revenue grew by 8.79% to 1.34 billion yuan, with a proposed cash dividend of 4 yuan per 10 shares [33][34] Group 17: 金龙羽 - Company experienced a 14.14% decrease in net profit for 2024, amounting to 14 million yuan [35] - Revenue decreased by 6.53% to 3.675 billion yuan, with a proposed cash dividend of 3 yuan per 10 shares [35][36] Group 18: 恒帅股份 - Company reported a 5.75% increase in net profit for 2024, totaling 214 million yuan [37] - Revenue increased by 4.21% to 962 million yuan, with a proposed cash dividend of 4 yuan per 10 shares and a stock bonus of 4 shares for every 10 shares held [37][38] Group 19: 爱玛科技 - Company expects a 25.12% increase in net profit for the first quarter of 2025, amounting to 605 million yuan [39] - Main business includes the development, production, and sales of electric bicycles and motorcycles [39][40] Group 20: 西王食品 - Company reported a net loss of 444 million yuan for 2024, compared to a loss of 16.8658 million yuan in 2023 [41] - Revenue decreased by 9.43% to 4.972 billion yuan [41][42]

公募基金方面本期较上一季度持股减少的公募基金共计3个，包括南方中证1000ETF、博时科创 100ETF、民生加银鑫喜混合，持股减少占比达0.40%。本期较上一季度新披露的公募基金共计111个， 主要包括科创100ETF基金、科创100、华夏上证科创板100ETF、华夏中证1000ETF、广发中证1000ETF 等。本期较上一季未再披露的公募基金共计8个，主要包括中海优质成长混合、招商瑞乐6个月持有期混 合A、招商瑞享1年持有期混合A、华西研究精选混合发起、长信稳健成长混合A等。 2025年4月3日，博瑞医药(688166.SH)发布2024年年度报告。截至2025年4月02日，共有120个机构投资 者披露持有博瑞医药A股股份，合计持股量达8575.65万股，占博瑞医药总股本的20.30%。其中，前十 大机构投资者包括苏州博瑞鑫稳管理咨询合伙企业(有限合伙)、先进制造产业投资基金(有限合伙)、中 国银行股份有限公司-招商优势企业灵活配置混合型证券投资基金、杭州茗嘉一期创业投资合伙企业(有 限合伙)、中国工商银行股份有限公司-博时上证科创板100交易型开放式指数证券投资基金、北京红杉 坤德投资管理中心(有限合伙 ...

2025年4月2日，博瑞医药发布了2024年年报。报告显示，公司全年实现营业收入12.83亿元，同比增长 8.74%；归属于上市公司股东的净利润为1.89亿元，同比下降6.57%。尽管营收有所增长，但净利润的持 续下滑引发了市场对其未来盈利能力的担忧。 博瑞医药在研发创新方面持续加大投入，2024年研发费用为3.12亿元，同比增长25.42%，占营业收入的 24.31%。公司重点布局代谢疾病领域，尤其是GLP-1类药物的研发，并持续推进BGM0504注射液等创 新药的研发。 然而，技术收入却大幅下降48.26%，仅为3921.77万元。这一骤降表明公司在技术转让或服务订单方面 遇到了较大挑战，可能与其技术开发进度或市场需求变化有关。尽管研发投入增加，但技术收入的显著 下滑无疑削弱了公司的整体盈利能力。 全球化布局持续推进，但海外权益分成收入下降3.02% 博瑞医药积极布局全球化战略，产品覆盖中国、欧盟、美国、日韩等多个国家和地区。2024年，公司海 外权益分成收入为6003.68万元，同比下降3.02%。尽管公司在海外市场的渠道扩展取得了一定成效，但 权益分成收入的下降表明其海外合作产品的市场表现趋于稳定，缺 ...

民生证券股份有限公司 关于博瑞生物医药（苏州）股份有限公司 保荐机构 民生证券股份有限公司 上市公司简称 博瑞医药 保荐代表人 黄丹青、邵航 上市公司代码 688166 经中国证券监督管理委员会《关于同意博瑞生物医药（苏州）股份有限公司 首次公开发行股票注册的批复》 （证监许可〔2019〕1883 号）核准，并经上海证 券交易所同意，博瑞生物医药（苏州）股份有限公司（以下简称"博瑞医药"或 "公司"）向社会公众公开发行人民币普通股（A 股）股票 41,000,000 股，每股 发行价格为人民币 12.71 元，募集资金总额 521,110,000.00 元，扣除承销及保荐 费用、会计师费用、律师费用、信息披露费用及其他发行手续费共计人民币 于 2019 年 10 月 31 日全部到位，且经公证天业会计师事务所（特殊普通合伙） 审验并出具了苏公 W2019B079 号《验资报告》。 年 11 月 18 日，博瑞医药以简易程序向特定对象发行股票。民生证券股份有限公 司（以下简称"民生证券"或"保荐机构"）作为博瑞医药首次公开发行股票、 向不特定对象发行可转换公司债券和以简易程序向特定对象发行股票的保荐机 构，根据 ...

博瑞生物医药（苏州）股份有限公司 审计报告 公证天业会计师事务所(特殊普通合伙) Gongzheng Tianye Certified Public Accountants, SGP 中国 . 江苏 . 无锡 Wuxi . Jiangsu . China | 总机：86（510）68798988 | Tel：86（510）68798988 | | --- | --- | | 传真：86（510）68567788 | Fax：86（510）68567788 | | 电子信箱：mail@gztycpa.cn | E-mail：mail@gztycpa.cn | | 审 计 报 告 | | 苏公 W2025A179 号 博瑞生物医药（苏州）股份有限公司全体股东： 一、审计意见 我们审计了博瑞生物医药（苏州）股份有限公司（以下简称"博瑞医药"） 财务报表，包括2024年12月31日的合并及母公司资产负债表，2024年度的合并及 母公司利润表、合并及母公司现金流量表、合并及母公司所有者权益变动表以及 相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制， 公允反映了博瑞医药2024年12 ...

Overview - The company plans to apply for a comprehensive credit limit of up to 3 billion RMB for the year 2025 to meet its operational needs, including working capital loans and project loans [1][2][24] - The credit will involve mutual guarantees among the company and its subsidiaries within the consolidated financial statements [1][22] Company Details - The company, 博瑞生物医药 (Suzhou) Co., Ltd., is involved in the production of various pharmaceutical forms, including tablets and injections, and has a significant focus on drug research and development [2][3] - As of December 31, 2023, the total assets of 博瑞制药 (Suzhou) Co., Ltd. were 571.92 million RMB, with total liabilities of 294.73 million RMB and net assets of 277.19 million RMB [2][3] - The company reported an operating income of 701.75 million RMB and a net profit of 78.42 million RMB for the year 2023 [2][3] Financial Structure - The company has a total of 113.96 million RMB in guarantees provided to its subsidiaries, which represents 47.59% of the company's audited net assets for 2024 [23][24] - The company has no overdue guarantees as of December 31, 2024 [23] Board Approval - The proposal for the credit application and mutual guarantees was approved during the fourth meeting of the fourth board of directors on April 1, 2025, and will be submitted for shareholder approval [23][24]

民生证券股份有限公司 关于博瑞生物医药（苏州）股份有限公司 参与设立创业投资基金暨关联交易的核查意见 民生证券股份有限公司（以下简称"民生证券"）作为博瑞生物医药（苏州） 股份有限公司（以下简称"博瑞医药"或"公司"） 首次公开发行股票并在科 创板上市以及向不特定对象发行可转换公司债券、以简易程序向特定对象发行股 票的保荐机构，履行持续督导职责，并根据《证券发行上市保荐业务管理办法》 《上海证券交易所科创板股票上市规则》等规范性法律文件的要求，对博瑞医药 参与设立创业投资基金暨关联交易事宜进行了审慎核查，核查情况及意见如下： 一、对外投资暨关联交易概述 为借助专业投资机构的经验和资源，拓宽投资方式和渠道，把握公司所在行 业的投资机会，公司拟与南京瑞弘熠鑫企业管理合伙企业（有限合伙）、南京江 北新区高质量发展产业投资基金（有限合伙）、南京生物医药谷建设发展有限公 司（"南京药谷"）、南京扬子国资投资集团有限责任公司、南京北联创业投资 有限公司、南京江北新区新城科技创业有限公司、南京高新创业投资有限公司、 上海鑫欣生物科技有限公司、维亚宗晨生物科技（杭州）有限公司、江苏鼎泰药 物研究（集团）股份有限公司共同投资设 ...

Core Insights - The company reported a total operating revenue of 1.283 billion yuan in 2024, representing a year-on-year growth of 8.74% [1] - The net profit attributable to shareholders decreased by 6.57% to 189 million yuan [1] - The company continues its dividend policy, proposing a cash dividend of 0.96 yuan per 10 shares, totaling an expected distribution of 40.52 million yuan [2] Revenue Breakdown - Revenue from raw materials reached 988 million yuan, an increase of 11.57% year-on-year [1] - Revenue from formulation products was 161 million yuan, growing by 16.77% year-on-year [1] - Antiviral product revenue decreased by 37.92% due to fluctuations in demand and pricing of oseltamivir [1] - Revenue from antifungal products surged by 60.28% due to increased commercialization demand [1] - Immunosuppressive product revenue grew by 45.72% driven by commercial demand [1] International Expansion - The company experienced a significant 45% increase in overseas revenue, attributed to expanded channels in North America and Europe [1] - The company has established multiple technology platforms to support the development of high-end generics and original new drugs [1] - Products have been registered and authorized for sale in the US, Europe, Japan, South Korea, and countries along the "Belt and Road" initiative, laying a solid foundation for future overseas revenue growth [1] R&D Investment - The company increased its R&D expenditure to 297 million yuan in 2024, a year-on-year increase of 19.65% [2] - Future R&D focus areas include treatments for NASH and dual-target drugs, with a particular emphasis on GLP-1 class drugs in the metabolic field [2] - The company aims to explore new administration methods, multi-target combination therapies, and expand indications to address unmet clinical needs [2] Dividend Policy - The company has maintained a consistent dividend policy since its listing in 2019, with cumulative cash dividends amounting to 246 million yuan over six years [2]

证券代码：688166 证券简称：博瑞医药 公告编号：2025-011 博瑞生物医药（苏州）股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 拟聘任的会计师事务所名称：公证天业会计师事务所（特殊普通合 伙） 一、拟聘任会计师事务所的基本情况 （一）机构信息 （1）会计师事务所名称：公证天业会计师事务所（特殊普通合伙） （2）成立日期：公证天业创立于 1982 年，是全国首批经批准具有从事证券、 期货相关业务资格及金融业务审计资格的会计师事务所之一。2013 年 9 月 18 日， 转制为特殊普通合伙企业。 （3）组织形式：特殊普通合伙企业 （4）注册地址：无锡市太湖新城嘉业财富中心 5-1001 室 （5）执行事务合伙人/首席合伙人：张彩斌 （6）截至 2024 年末，公证天业合伙人数量 59 人，注册会计师人数 349 人， 签署过证券服务业务审计报告的注册会计师人数 168 人。 （7）公证天业 2024 年度经审计的收入总额 30,857.26 万元，其中审计业务 收入 26,545. ...

Group 1 - The company conducted an evaluation of the independence of its independent directors, confirming that all three independent directors meet the independence requirements set by relevant regulations [1] - The independent directors, Cheng Zengjiang, Xu Dongdong, and Wu Yinghua, have no conflicts of interest with the company or its major shareholders, allowing them to perform their duties independently [1] - The board of directors affirmed that the independent directors maintained a high level of independence throughout the year 2024, providing impartial and professional opinions for the company's decision-making [1]